Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...

Eli Lilly (LLY) remains a core holding at 7% of NAV, but I have trimmed my position by 50% after a 38.8% price return since purchasing earlier in 2025. I have taken the proceeds and increased my MP ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Nov. 21 (UPI) --Healthcare giant Eli Lilly on Friday became the first global healthcare company to hit $1 trillion in value. The Indiana-based company hit the $1 trillion market capitalization ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...